Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia
Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia
A randomized, open label, dose titration study to evaluate the efficacy and safety of
 Pitavastatin compared to atorvastatin in Type 2 Diabetes Mellitus with hypercholesterolemia
To evaluate the effect of pitavastatin compared to atorvastatin on the change of Lipid
 profiles, ApoA1, ApoB, adiponectin and baPWV as a marker of atherosclerosis in Type 2DM .
Inclusion Criteria:

 -  Age: 25yrs~75yrs

 -  Fasting TG <400mg/dL, LDL-C ≥130mg/dL

 -  3months > Diagnosed Type2 DM, With OAD, HbA1c ≤ 10.0% or First Diagnosed Type2 DM,
 6.5%≤HbA1c≤10.0%

 Exclusion Criteria:

 -  Type1 DM, Gestational diabetes

 -  Patient need to treat with Insulin

 -  Patient with operational treatment for severe diabetic complication

 -  Uncontrolled Hypothyroidism

 -  Unstable angina, MI, transient ischemic attack(TIA), Stroke, PCI, Heart Failure within
 3 months (NYHA class4)

 -  Severe Hypertension (SBP ≥ 180 or DBP ≥ 110mmHg)

 -  Renal disorder (Serum creatinine ≥ 2.0mg/dL)

 -  Hepatic disorder (AST or ALT ≥ 2.5 X UNL)

 -  Creatinine Kinase > 2.5 X UNL

 -  Gravida or lactation phase

 -  Administration of Atorvastatin, Rosuvastatin, Pitavastatin